Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Morning Review
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
    • Insider Transactions
  • inderesTV
  • Portfolio
  • Forum
  • Premium
  • Femme
  • Nora AI
  • Learn
    • Investing School
    • Q&A
    • Analysis School
  • About Us
    • Our Coverage
    • Team
Press release

Redeye: CLS Q3 - An eventful quarter

Clinical Laserthermia Systems

Redeye provides an update in relation to CLS’ Q3 2023 report. Net sales during the quarter amounted to SEK2.0m (SEK0.9m), and EBIT came in at SEK-15.6m (SEK-27.0m) compared to our sales estimate of SEK3.5m and EBIT estimate of SEK-18.7m. Overall, we are positive about the report, as CLS has been cost-effective, and the news flow has been solid. We only make some minor changes in our model, resulting in an updated fair value range (SEK0.15-0.8); however, our base case remains at SEK0.4.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments


CLS Q3 - An eventful quarter

Find us on social media
  • Inderes Forum
  • Youtube
  • Facebook
  • Instagram
  • X (Twitter)
  • Tiktok
  • Linkedin
Get in touch
  • info@inderes.fi
  • +358 10 219 4690
  • Porkkalankatu 5
    00180 Helsinki
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.